I have a compound from a repurposing screen; would this be in scope?

This would depend on the novelty of repurposing. For example, expanding the label of an approved antibiotic would not be in scope, while repurposing or repositioning of a drug approved in a different disease context may be in scope if there is a clear rationale for direct or indirect antimicrobial properties and a need for activities within hit-lead and/or lead optimisation.